Agios Pharmaceuticals, Inc. Appoints Jay Backstrom to Board of Directors and Science and Technology Committee

Published: 2025-07-08 07:50:32 ET AGIO

Published on 07/08/2025 at 07:50

Agios Pharmaceuticals, Inc. announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. Dr. Backstrom brings decades of leadership experience spanning large pharmaceutical companies, mid-sized biotech firms, and early-stage biopharma organizations.

Most recently, as President and Chief Executive Officer of Scholar Rock, he led a strategic pipeline review and advanced the company?s lead spinal muscular atrophy program through Phase 3 development and regulatory filings in both the U.S. and European Union. Previously, he served as Executive Vice President of Research and Development at Acceleron Pharma, which was acquired by Merck in 2021, and as Chief Medical Officer and Head of Global Regulatory Affairs at Celgene Corporation. At Celgene, Dr. Backstrom led key efforts to expand the pipeline and played a pivotal role in advancing clinical programs that led to regulatory approvals in beta thalassemia and myelodysplastic syndromes.

Dr. Backstrom will serve on Agios? Science and Technology Committee.